\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital Europe AI ContinentThe European Commission has updated the available information on Simpl, an open source, smart and secure middleware platform that supports data access and interoperability among European data spaces on its dedicated website.
Project proposals under Digital Europe, especially proposals on calls that aim at the development and deployment of data spaces, are required to take developments on Simpl into account and foresee the use of Simpl in the course of the projects. It is therefore recommended to keep an eye on the Simpl website to stay up to date on relevant evolutions.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
Health Culture and society Security Digital, Industry & Space
The open and forthcoming calls under Horizon Europe have been published on the Funding & Tenders Portal (Funding - Call for proposals) However, there are technical issues with the filter functions in Pillar 2: filtering per cluster does not display all 2025 call topics within this cluster and advertise call topics of other work programmes. The... read more
The METHYLOMIC project, ‘targeting hope for personalised medicine in immune-mediated inflammatory diseases’ obtained funding from Horizon Europe’s Health Cluster. The project aims to personalise treatment allocation and enhance the effectiveness of medications for chronic immune-mediated diseases such as Crohn’s disease, rheumatoid arthritis, and psoriasis. BIRD, the Belgian inflammatory bowel disease research and development group, is a partner in the project and is involved in the OmiCrohn trial, a prospective randomised clinical trial for individualised therapy in Crohn’s disease patients. With BIRD’s active role in this trial, the project is set to deliver predictive, biomarker-based therapies that bring renewed hope for Crohn’s disease patients across Europe.
